Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Primary endpoint met: DAV132 was safe for use in hospitalized patients with several comorbidities and concomitant medications.
Lead Product(s): DAV132
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2020